

Remarks

Amendments to the Claims

Claims 1-43 were pending in this application. Claims 18-27 and 38-43 are cancelled herein as drawn to non-elected Groups. Applicants expressly reserve the right to pursue protection of any or all of the cancelled claims in a subsequent application.

No new matter is introduced by these amendments. After entry of this amendment, **claims 1-17 and 28-37 are pending in the application.**

Response to Restriction Requirement

In response to the Restriction Requirement, Applicants elect Examiner's Group I (nucleic acids encoding flaviviral antigens, claims 1-17 and 28-37) without traverse.


Conclusion

Examiner Parkin is invited to telephone the undersigned if any questions remain concerning the requirement for restriction, or the amendments made herein. Otherwise, the present application is ready for substantive examination, and such action is requested.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446